Antares Pharma (Antares Pharma) Float Percentage Of Total Shares Outstanding : 97.86% (As of May. 05, 2024)

View and export this data going back to 1996. Start your Free Trial

What is Antares Pharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Antares Pharma's float shares is 167.19 Mil. Antares Pharma's total shares outstanding is 170.85 Mil. Antares Pharma's float percentage of total shares outstanding is 97.86%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Antares Pharma's Insider Ownership is 10.39%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Antares Pharma's Institutional Ownership is 35.70%.

Antares Pharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Antares Pharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	167.19	/	170.85
	=	97.86%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antares Pharma (Antares Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Antares Pharma Inc (NAS:ATRS) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Princeton South, Suite 300, Ewing, NJ, USA, 08628

Website

https://www.antarespharma.com

Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.

Executives

Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Carmen B Volkart	director	C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127
Peter C Richardson	officer: See Remarks	28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Fred M Powell	officer: Executive Vice President & CFO	C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Thomas J Garrity	director
Roche Robert P Jr	director	41 MOORES ROAD FRAZER PA 19355
Leonard S Jacob	director	C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022
Peter J Graham	officer: See Remarks	315 E. 72ND ST., APT 5E, NEW YORK NY 10021
Peter Greenleaf	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anton Gueth	director
Robert F Apple	director, officer: President & CEO	C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422
Marvin Samson	director
Jacques Gonella	director	C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341
James Patrick Tursi	officer: EVP, Chief Medical Officer	106 ASHLEY COURT, MOORESTOWN NJ 08057
Keith E Muckenhirn	officer: VP/Controller & Interim CFO	C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447